Clinical Trials Sponsored by Suzhou Raymon Pharmaceuticals Company, Ltd.

Total 142 results

Suzhou Raymon Pharmaceuticals Company, Ltd.
WuXi Clinical

Active, not recruiting

RMP-A03 Ocular Suspension in Patients With Pterygium

Pterygium

United States
Mochida Pharmaceutical Company, Ltd.
Sumitomo Pharma (Suzhou) Co., Ltd.

Active, not recruiting

Efficacy of Ethyl Icosapentate in Patients With Severe Hypertriglyceridemia

Hypertriglyceridemia

China
3H (Suzhou) Pharmaceuticals Co., Ltd.

Not yet recruiting

A Study of 3HP-2827 in Treatment of Unresectable or Metastatic Solid Tumors With FGFR2 Alterations

Solid Tumors With FGFR2 Alterations, Adult

China
3H (Suzhou) Pharmaceuticals Co., Ltd.

Not yet recruiting

A First-in-human Study of 3HP-2827 in Patients With Unresectable or Metastatic Solid Tumors With FGFR2 Alterations

Solid Tumors With FGFR2 Alterations, Adult

United States
Suzhou Erye Pharmaceutical Co., Ltd.

Recruiting

Study of the Safety, Tolerability, and PK of SZEY-2108 Administered Intravenously to HVs in SAD and MAD Cohorts

Infections

China
Asclepius Technology Company Group (Suzhou) Co....

Unknown

Clinical Research of ROBO1 Specific CAR-NK Cells on Patients With Solid Tumors

Solid Tumor

China
Asclepius Technology Company Group (Suzhou) Co....

Unknown

Clinical Research of Adoptive BCMA CAR-NK Cells on Relapse/Refractory MM

Multiple Myeloma

China
Asclepius Technology Company Group (Suzhou) Co....

Unknown

Clinical Research of ROBO1 Specific BiCAR-NK/T Cells on Patients With Malignant Tumor

Malignant Tumor

China
Asclepius Technology Company Group (Suzhou) Co....

Unknown

Clinical Research of ROBO1 Specific BiCAR-NK Cells on Patients With Pancreatic Cancer

Pancreatic Cancer

China
Suzhou Puhe Pharmaceutical Technology Co., LTD

Not yet recruiting

YK-029A as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations

Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)

China
Suzhou Puhe Pharmaceutical Technology Co., LTD

Recruiting

Assessing an Oral EGFR Inhibitor,YK-209A in Patients Who Have Advanced Non-small Cell Lung Cancer With EGFR

Treatment Side Effects | Treatment

China
Heyu (Suzhou) Pharmaceutical Technology Co., Ltd

Recruiting

Phase I Clinical Study of HY01 in Patients

Sudden Sensorineural Hearing Loss

China
Keythera Pharmaceuticals (Australia) Pty Ltd

Recruiting

A Study of KF-0210 in Advanced Solid Tumors Patients

Gastric Cancer | Colorectal Cancer | Lung Cancer | Bladder Cancer | Advanced Solid Tumor | Squamous Cell Carcinoma of the Esophagus

Australia
Reyon Pharmaceutical Co., Ltd.

Completed

Safety Study of VM206RY in Subjects With Expression of HER2 in Breast Cancer (VM206RY)

Breast Cancer

Korea, Republic of
Mochida Pharmaceutical Company, Ltd.

Completed

Long-term Safety and Efficacy Study of MND-2119 in Patients With Hypertriglyceridemia

Hypertriglyceridemia

Japan
Mochida Pharmaceutical Company, Ltd.

Completed

Utility of Presepsin in Distinguishing Between Sepsis and SIRS

Sepsis | SIRS

United States
Mochida Pharmaceutical Company, Ltd.

Completed

Double-Blind, Placebo-Controlled Study of Two Doses of EPA-E in Patients With Non Alcoholic Steatohepatitis (NASH)

Steatohepatitis

United States, Puerto Rico
Mochida Pharmaceutical Company, Ltd.

Completed

Efficacy of MND-2119 in Participants With Hypertriglyceridemia

Hypertriglyceridemia

Japan
Mochida Pharmaceutical Company, Ltd.

Completed

Study Evaluating Single Ascending Doses of MR1817

Adult

United Kingdom
Huashan Hospital
Sumitomo Pharmaceuticals (Suzhou) Co. Ltd

Unknown

WGS-guided Tracking and Infection Control Measures of CRKP

Klebsiella Pneumoniae Infection

China
Inovio Pharmaceuticals
Advaccine (Suzhou) Biopharmaceuticals Co., Ltd.

Terminated

Safety, Immunogenicity, and Efficacy of INO-4800 for COVID-19 in Adults at High Risk of SARS-CoV-2 Exposure

Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) | Coronavirus Infection | COVID-19 Disease

United States, Mexico, Colombia
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
CStone Pharmaceuticals

Recruiting

A Study of CS1001 in Combination With Donafenib in Subjects With Advanced Solid Tumors

Advanced Solid Tumor

China
Suzhou Yabao Pharmaceutical R&D Co., Ltd.

Suspended

SY007 in Patients With Acute Ischemic Stroke

Acute Ischemic Stroke

China
Suzhou Yabao Pharmaceutical R&D Co., Ltd.

Completed

A Drug Interaction Study of SY-004 Capsules in Healthy Subjects

Type 2 Diabetes

China
Suzhou Yabao Pharmaceutical R&D Co., Ltd.

Completed

Multiple Ascending Doses of SY-009 in Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus

China
Suzhou Yabao Pharmaceutical R&D Co., Ltd.

Completed

Single Ascending Oral Doses of SY-009 in Healthy Subjects

Diabetes

China
Suzhou Yabao Pharmaceutical R&D Co., Ltd.

Completed

Single Ascending Oral Doses of SY-008 in Healthy Subjects

Diabetes

China
Jiesi Yingda Pharmaceutical Technology (Suzhou)...

Recruiting

VIC-1911 Combined With Osimertinib for EGFR -Mutant Non-small Cell Lung Cancer (VIC-1911)

Advanced Non-small Cell Lung Cancer

China
Suzhou Yabao Pharmaceutical R&D Co., Ltd.

Not yet recruiting

The Efficacy and Safety of Different Doses of SY-009 in Patients With Type 2 Diabetes Mellitus

Type 2 Diabetes

China
Suzhou Yabao Pharmaceutical R&D Co., Ltd.

Recruiting

SY-005 （Recombinant Human Annexin A5）in Patients With Sepsis

Sepsis

China
Suzhou Yabao Pharmaceutical R&D Co., Ltd.

Completed

A Food-drug Interaction Study of SY-004 in Healthy Subjects

Type 2 Diabetes

China
Suzhou Yabao Pharmaceutical R&D Co., Ltd.

Completed

Single-dose/Multiple-doses Incremental Intravenous Injection of SY-005 （Recombinant Human Annexin A5）in Healthy Subjects

Sepsis

China
Suzhou Yabao Pharmaceutical R&D Co., Ltd.

Completed

Single-dose Incremental Intravenous Injection of SY-007 in Healthy Subjects

Cerebral Apoplexy

China
Suzhou Yabao Pharmaceutical R&D Co., Ltd.

Completed

The Efficacy and Safety of Different Doses of SY-004 in Patients With Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus

China
Suzhou Yabao Pharmaceutical R&D Co., Ltd.

Completed

Multiple Ascending Doses of SY-008 in Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus

China
Guangzhou Lupeng Pharmaceutical Company LTD.

Completed

The Mass Balance Study of LP-168 in Healthy Subjects

Clinical Pharmacology

China
Guangzhou Lupeng Pharmaceutical Company LTD.

Active, not recruiting

A Study of LP-128 Capsules in Healthy Subjects

Chronic Hepatitis b

China
Guangzhou Lupeng Pharmaceutical Company LTD.

Completed

A Food Effect Study of LP-168 Tablets in Healthy Subjects

Mantle Cell Lymphoma

China
Guangzhou Lupeng Pharmaceutical Company LTD.

Completed

A Study of LP-168 in Healthy Volunteers

Multiple Sclerosis | NMO Spectrum Disorder

China
Guangzhou Lupeng Pharmaceutical Company LTD.

Recruiting

A Study to Assess Safety and Preliminary Efficacy of LP-108 Combined With Azacitidine In Subjects With AML, MDS, CMML

Acute Myeloid Leukemia | Myelodysplastic Syndromes | Chronic Myelomonocytic Leukemia

China
Guangzhou Lupeng Pharmaceutical Company LTD.

Recruiting

A Study of LP-168 in Participants With Relapse or Refractory B-Cell Lymphoma

B-cell Lymphoma

China
Guangzhou Lupeng Pharmaceutical Company LTD.

Recruiting

Phase Ib Study of Rocbrutinib in Combination With R-CHOP in Patients With Newly Diagnosed B-cell Non-Hodgkin Lymphoma

B-cell Non-Hodgkin Lymphoma

China
Guangzhou Lupeng Pharmaceutical Company LTD.

Recruiting

A Study of LP-168 in Participants With Relapse or Refractory Mantle Cell Lymphoma

Mantle Cell Lymphoma (MCL)

China
Guangzhou Lupeng Pharmaceutical Company LTD.

Recruiting

A Study of LP-118 in Patients With Advanced Tumors

Lymphoma, Non-Hodgkin | Solid Tumor

China
Mochida Pharmaceutical Company, Ltd.
Pfizer

Completed

A Study of MD-120 in Patients With Depression

Major Depressive Disorder

Japan
Ascentage Pharma Group Inc.
Suzhou Yasheng Pharmaceutical Co., Ltd.

Recruiting

APG-115 Alone or in Combination With APG-2575 in Children With Recurrent or Refractory Neuroblastoma or Solid Tumors

Solid Tumor | Neuroblastoma

China
Ascentage Pharma Group Inc.
Suzhou Yasheng Pharmaceutical Co., Ltd.

Recruiting

APG-115 in Combination With PD-1 Inhibitor in Patients With Advanced Liposarcoma or Advanced Solid Tumors

Advanced Solid Tumor | Liposarcoma

China
Ascentage Pharma Group Inc.
Suzhou Yasheng Pharmaceutical Co., Ltd.

Recruiting

APG-2449 in Patients With Advanced Solid Tumors

Esophageal Cancer | Ovarian Cancer | Non Small Cell Lung Cancer | Malignant Pleural Mesothelioma | Advanced Solid Cancer

China
Ascentage Pharma Group Inc.
Suzhou Yasheng Pharmaceutical Co., Ltd.

Terminated

APG-1252 in Patients With SCLC or Advanced Solid Tumors

Small Cell Lung Cancer and Other Solid Tumors

China
Beijing Grand Johamu Pharmaceutical Company, Ltd.

Recruiting

A Retrospective, Real-world Study of ELP Used in the Expectorant Treatment of Community-acquired Pneumonia

Community-acquired Pneumonia

China

Clinical Trials Sponsored by Suzhou Raymon Pharmaceuticals Company, Ltd.

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Norway

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations